Matthew Donnan

Dr. Matthew Donnan


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2025 in International Journal of Chronic Obstructive Pulmonary Disease
Verified
Journal Article
Open access
PDF file
MDMatthew Donnan
Matthew Donnan
TLTong Lei Liu
Tong Lei Liu
MGMatthew Gvalda
Matthew Gvalda
XCXinye Chen
Xinye Chen
CFChuan T Foo
Chuan T Foo
FTFrancis Thien
Francis Thien
Introduction: The role of eosinophilic inflammation in exacerbations of chronic obstructive pulmonary disease (COPD) is increasingly recognised. Eosinophilic exacerbations have previously been associated with shorter hospital length of stay and lower inpatient mortality. The objective of this study was to examine clinical characteristics of hospitalised COPD exacerbations stratified by admission eosinophil count. Methods: We performed a retrospective cohort study of exacerbations of COPD at an Australian tertiary health service between 1st October 2019 and 30th September 2020 that were identified using ICD-10 discharge codes. Patients were excluded if they received any systemic corticosteroids prior to hospitalisation. Admissions were stratified according to blood eosinophil count as high eosinophil (HE, ≥ 2% total white blood cell count), or low eosinophil (LE, < 2%). Results: Four hundred and six patients were analysed. HE patients were younger (74.7 vs 77.7 years, p=0.001) and had fewer co-morbidities (1 [1– 2] vs 2 [1– 3], p=0.044). Patients with HE were less likely to be taking inhaled corticosteroids (59% vs 71%, p=0.017). HE exacerbations had a higher blood eosinophil count (0.31 vs 0.06 × 109/L, p< 0.0001), lower total white cell count (8.45 vs 10.6, p< 0.001), lower CRP (10.4 vs 26.7, p< 0.001), fewer infections (29.5% vs 52.1%, p< 0.001) and less oxygen requirement (35.2% vs 46.8%, p=0.036). HE exacerbations had a shorter length of stay (3.56 vs 4.40 days, p=0.047) but similar inpatient mortality. Discussion: Eosinophilic exacerbations of COPD were phenotypically different, affect a younger, less co-morbid population and were associated with shorter length of stay. This may be useful to help prognosticate clinical outcomes and guide clinical management. Plain Language Summary: Exacerbations of COPD are common and carry high morbidity and mortality. Some exacerbations are associated with eosinophilic inflammation, but greater detail surrounding the relationship between eosinophils and exacerbations of COPD is needed. In our study, eosinophilic exacerbations of COPD were found to affect a younger, less co-morbid population, were less likely to be associated with infection, require less oxygen and were associated with shorter length of stay, but had similar rates of inpatient mortality.

29 January 2025 in Internal Medicine Journal
Verified
Journal Article
Open access
MMMaitri Munsif
Maitri Munsif
MDMatthew Donnan
Matthew Donnan
GSGregory Snell
Gregory Snell
KLKovi Levin
Kovi Levin
MPMiranda Paraskeva
Miranda Paraskeva
Background: Return‐to‐work (RTW) following lung transplant has been associated with increased quality of life, but little is known regarding the rates of and barriers to this in the Australian population.Aims: We aimed to describe, characterise and determine predictors of return to work and social participation in Australian lung transplant recipients. We also sought to explore the relationship between return to work and quality of life.Methods: We conducted a cross‐sectional questionnaire‐based study at the Alfred Hospital, Melbourne between October 2018 and August 2019. The questionnaire evaluated demographics, transplant history, respiratory parameters, employment history and social integration prior to and after lung transplantation.Results: A total of 172 lung transplant recipients were included for analysis. The population was mostly male (56.5%), median age 61 years (interquartile range (IQR) 49.8–67.0) and median time from transplant 4 years (IQR 2–7). A total of 19.2% of patients were working at time of transplant, with 35.5% working after transplant representing an increase in workforce engagement of 84.8% (P < 0.001). A total of 96% of those who returned to work reported an improvement in quality of life. Median time to RTW after transplant was 180 days (IQR 90–360). Multivariable analysis demonstrated an increased rate of RTW in younger recipients (odds ratio (OR) 0.94, 95% confidence interval (CI) 0.89–0.99, adjusted P = 0.029), at greater length of time after transplant (OR 1.09, 95% CI 0.99–1.19, P = 0.084), among those working at the time of transplant (OR 9.55, 95% CI 2.70–33.75, P < 0.001) and with higher socioeconomic status (OR 1.02, 95% CI 1.01–1.04, P = 0.009). Recipients with cystic fibrosis were more likely to RTW (65.8%) than those with other underlying conditions.Conclusions: RTW should be encouraged in lung transplant recipients. Targeted supports and resources aimed at younger recipients may result in greater workforce engagement and overall outcomes after transplant.

15 July 2024 in Respirology Case Reports
Verified
Journal Article
Open access
MDMatthew Donnan
Matthew Donnan
MSMiranda Siemienowicz
Miranda Siemienowicz
HTHui Sien Tay
Hui Sien Tay
CMCatriona McLean
Catriona McLean
SPSteve Philpot
Steve Philpot
RSRob Stirling
Rob Stirling
Trimethoprim‐sulfamethoxazole (TMP‐SMX) acute respiratory distress syndrome (ARDS) is a rare, but severe complication of a commonly prescribed antibiotic. TMP‐SMX typically affects young, otherwise well patients with a specific human leukocyte antigen type (HLA‐B*07:02 and HLA‐C*07:02). The condition is poorly understood with a unique pathological appearance and mechanism that remains unclear. Mortality rate is greater than one third. We describe the case of a previously well 18‐year‐old woman treated with a prolonged course of TMP‐SMX for a complex urinary tract infection who developed rapidly progressive respiratory failure requiring prolonged intensive care admission, extra‐corporeal membranous oxygenation, and eventual lung transplantation. No targeted treatment exists, further research is required to better understand disease pathogenetic mechanisms and potential therapeutic interventions.

26 September 2024 in Respiratory Medicine Case Reports
Verified
Journal Article
Open access
MDMatthew Donnan
Matthew Donnan
SESamantha Ellis
Samantha Ellis
IGIan Glaspole
Ian Glaspole
Hermansky-Pudlak Syndrome is a rare genetic cause of pulmonary fibrosis, associated with albinism, nystagmus, and a bleeding diathesis. Histologically, Hermansky-Pudlak Syndrome Pulmonary Fibrosis (HPS-PF) typically resembles usual interstitial pneumonia (UIP), however radiologically this is not always the case with a range of features described in the current literature. HPS-PF typically occurs earlier in life than idiopathic pulmonary fibrosis (IPF) and there is limited evidence to support the use of antifibrotic therapy. Given the rarity and potential clinical outcomes of the disease, further research is required. This may be aided by the inclusion of patient with HPS-PF in registry databases.

27 February 2025 in Critical Care and Resuscitation
Verified
Journal Article
Open access
MDMatthew Donnan
Matthew Donnan
PZPeinan Zhao
Peinan Zhao
ACAllen C. Cheng
Allen C. Cheng
AIAaliya Ibrahim
Aaliya Ibrahim
APAnnamaria Palermo
Annamaria Palermo
ABAidan Burrell
Aidan Burrell
To describe and compare the demographics, management, and outcomes for patients with COVID-19 admitted to intensive care units (ICUs) in Australia across the various waves of the COVID pandemic. People aged ≥16 years who were admitted to a participating ICU with confirmed COVID-19 in the Short Period Incidence Study of Severe Acute Respiratory Infection (SPRINT-SARI) Australia study between February 2020 and May 2024. Primary outcome: In-hospital mortality. Secondary outcomes: ICU mortality; ICU and hospital lengths of stay; supportive and disease-specific therapies. From 27 February 2020 to 18 May 2024, 10171 people were admitted to 72 ICUs with confirmed COVID-19 disease. The Wild Type wave included 518 (5.1%) patients, the Delta wave 2467 (24.3%) patients, and the Omicron wave 7186 (70.7%) patients. The median (IQR) age was 61 (49-70) years, 54 (41-66) years, and 65 (45-75) years, respectively (P < 0.001). The proportion of vaccinated cases increased in successive waves (1% vs 23.9% vs 65.1%) but plateaued in the Omicron subvariant waves (range 60.0%-71.9%). Invasive mechanical ventilation use decreased across successive waves (52.5% vs 43.6% vs 31.7%, P < 0.001). Use of extracorporeal membrane oxygenation was highest during the Delta wave (3.6%, 83 patients, median duration 18 days [IQR 9.8-35]). Multivariable analysis demonstrated an increased risk of in-hospital mortality among patients admitted during the Delta (adjusted HR 1.80, 95% CI: 1.38-2.35, p < 0.001) and Omicron (adjusted HR 1.88, 95% CI: 1.46-2.42, p < 0.001) waves when compared to the Wild Type wave. COVID-19 continues to manifest significant morbidity and mortality in those requiring ICU admission. Despite a reduced need for ICU level supports, patients admitted during the Omicron wave demonstrated the highest in-hospital mortality.

17 May 2024 in Respirology Case Reports
Verified
Journal Article
Open access
MDMatthew Donnan
Matthew Donnan
EDEli Dabscheck
Eli Dabscheck
BMBelinda R. Miller
Belinda R. Miller
SESamantha J. Ellis
Samantha J. Ellis
MNMatthew T. Naughton
Matthew T. Naughton
Key message: Swyer‐James‐MacLeod Syndrome is a rare obliterative lung disease typically caused by childhood infection resulting in arrested pulmonary development. Imaging findings include unilateral hyperlucency on chest x‐ray, and hyperlucency, hypovascularity and expiratory gas trapping on computed tomography. Recognition of abnormal imaging can lead to earlier diagnosis and institution of appropriate management.